EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer  by van Driel, Pieter B.A.A. et al.
Journal of Controlled Release 229 (2016) 93–105
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lEGFR targeted nanobody–photosensitizer conjugates for photodynamic
therapy in a pre-clinical model of head and neck cancerPieter B.A.A. van Driel a,b,1,2, Martin C. Boonstra c,1, Maxime D. Slooter a,b,2, Raimond Heukers d,
Marieke A. Stammes a,b,2, Thomas J.A. Snoeks a, Henriette S. de Bruijn e, Paul J. van Diest f,
Alexander L. Vahrmeijer c, Paul M.P. van Bergen en Henegouwen d, Cornelis J.H. van de Velde c,
Clemens W.G.M. Löwik a,2, Dominic J. Robinson e, Sabrina Oliveira d,⁎
a Department of Radiology, Division of Molecular Imaging, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
b Percuros BV, Drienerlolaan 5, 7522 NB Enschede, The Netherlands
c Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
d Molecular Oncology, Cell Biology Division, Department of Biology, Faculty of Science, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
e Department of Otorhinolaryngology & Head and Neck Surgery, Center for Optical Diagnostics and Therapy, Erasmus Medical Center, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
f Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands⁎ Corresponding author at: Molecular Oncology (Room
Department of Biology, Faculty of Science, Utrecht Uni
Utrecht, The Netherlands.
E-mail address: s.oliveira@uu.nl (S. Oliveira).
1 Both authors contributed equally to this work and sha
2 Current address: Department of Radiology, Division
Erasmus Medical Center, s-Gravendijkwal 230, 3015 CE R
http://dx.doi.org/10.1016/j.jconrel.2016.03.014
0168-3659/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 16 December 2015
Received in revised form 7 March 2016
Accepted 9 March 2016
Available online 15 March 2016Photodynamic therapy (PDT) induces cell death through local light activation of a photosensitizer (PS) and has been
used to treat head and neck cancers. Yet, commonPS lack tumor speciﬁcity,which leads to collateral damage to nor-
mal tissues. Targeteddelivery of PS via antibodies has pre-clinically improved tumor selectivity. However, antibodies
have long half-lives and relatively poor tissue penetration, which could limit therapeutic efﬁcacy and lead to long
photosensitivity. Here, in this feasibility study, we evaluate at the pre-clinical level a recently introduced format of
targeted PDT,which employs nanobodies as targeting agents and awater-soluble PS (IRDye700DX) that is traceable
through optical imaging. In vitro, the PS solely binds to cells and induces phototoxicity on cells overexpressing the
epidermal growth factor receptor (EGFR),when conjugated to the EGFR targeted nanobodies. To investigatewheth-
er this new format of targeted PDT is capable of inducing selective tumor cell death in vivo, PDT was applied on an
orthotopic mouse tumor model with illumination at 1 h post-injection of the nanobody–PS conjugates, as selected
fromquantitative ﬂuorescence spectroscopymeasurements. In parallel, and as a reference, PDTwas appliedwith an
antibody–PS conjugate, with illumination performed 24 h post-injection. Importantly, EGFR targeted nanobody–PS
conjugates led to extensive tumor necrosis (approx. 90%) and almost no toxicity in healthy tissues, as observed
through histology 24 h after PDT. Overall, results show that these EGFR targeted nanobody–PS conjugates are selec-
tive and able to induce tumor cell death in vivo. Additional studies are now needed to assess the full potential of this
approach to improving PDT.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Head and neck cancer1. Introduction
Cancers of the head and neck region are the sixth most common
cancers in the world [1]. In spite of recent advances in surgery and
radiotherapy, increasing incidences and moderate survival rates are re-
ported [2]. Photodynamic therapy (PDT) is a promisingminimally inva-
sive approach that is being used for the local treatment of premalignant
and malignant lesions in the head and neck region [3,4]. Despite theN510), Division of Cell Biology,
versity, Padualaan 8, 3584 CH
re ﬁrst-authorship.
of Optical Molecular Imaging,
otterdam, The Netherlands.
. This is an open access article underpotential advantages of PDT, collateral damage to normal tissue remains
a signiﬁcant side effect, particularly in the treatment of large tumors [5].
Targeted PDT, in which photosensitizers (PS) are selectively delivered
to the tumor, could greatly enhance the results of PDT in head and
neck cancer.
PDT makes use of three essential elements to induce localized
(tumor) cell death: a PS, light of a particular wavelength, and oxygen
[3]. Although each of these individual components is not toxic, together
they induce local toxicity through the formation of toxic reactive oxygen
species, notably singlet oxygen (1O2), damaging proteins, lipids and/or
nucleic acids. The lifetime and diffusion distance of 1O2 are very short
[6], consequently, the localization of PS at the time of the illumination
is a critical factor in the selectivity of PDT. The overall localization of
the PS at the tumor and the surrounding normal tissues is determined
by the pharmacokinetics of the PS (i.e. its absorption, distribution,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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results in cell death through apoptosis and/or necrosis. Necrotic cell
death can be induced either by a direct effect on tumor cells or indirectly
through a shutdown of tumor vasculature. An important additional
mechanism of action in PDT is derived from a robust inﬂammatory re-
sponse that can lead to development of systemic immunity [3].
Clinically available PSs can be categorized as derivatives of three
major families: porphyrins (e.g. Photofrin), chlorins (e.g. Foscan) and
phthalocyanines (e.g. Photosense) [7]. In general, most PSs are rather
hydrophobic which promotes cell binding, but provides no speciﬁcity.
As a result, 2 to 4 days are generally necessary between injection of
the PS and illumination, in order to favor clearance of PS from normal
tissues and to promote some tumor speciﬁcity [7]. Alternatively, light
can be applied earlier after PS administration, with the particular inten-
tion to induce vascular damage [3]. In addition, patients generally show
skin photosensitivity for long periods of time (2–6 weeks) [3,8]. There-
fore, efforts have been made to render PS more hydrophilic and to target
these molecules more selectively to tumors, through chemical modiﬁca-
tions, delivery systems, and/or targeting molecules [9–13]. The targeting
of PS through the use of monoclonal antibodies (mAbs), which is termed
photoimmunotherapy [11], has shown promising results [14,15]. Never-
theless, due to their large molecular weight (150 kDa), mAb–PS conju-
gates have a limited capability of penetrating into the interior of large
tumors [16,17]. Moreover, the larger size of mAbs–PS conjugates
(~15 nm) may impede the generation of 1O2 within the outer cell mem-
brane of targeted cells and affect the therapeutic efﬁcacy. The location of
lipophilic photosensitisers within the plasma membrane has previously
been shown to inﬂuence in vitro and in vivo efﬁcacy [18]. Further-
more, because of long half-lives of mAbs in the bloodstream, time
is needed for tumor accumulation and development of sufﬁcient
tumor-to-background ratios (TBR) to protect healthy tissues. As many
of these disadvantages are related to the size of mAbs, some studies
reported the use of smaller mAb fragments such as F(ab′)2 and scFv con-
jugated to a PS [19–24].
Recently, we have introduced an alternative approach for targeted
PDT employing nanobodies conjugated to awater-soluble and traceable
PS, leading to encouraging results in vitro [25]. Nanobodies are the
smallest naturally derived antigen-binding fragments that consist of
the variable domain of heavy chain antibodies, which were ﬁrst discov-
ered in dromedaries in 1993 [26]. Nanobodies bind speciﬁcally andwith
high afﬁnities to their antigens [26,27], they are stable and soluble in
aqueous solutions, can be chemically modiﬁed, and have low immuno-
genic potential [28]. Importantly, with a molecular weight ten times
smaller than conventional antibodies (15 kDa vs 150 kDa) [29] and
high binding afﬁnities, tumor penetration of nanobodies is greatly en-
hanced, and occurs more rapidly [27,30,31] (this is in line with the
modeling of Schmidt andWittrup [32]). In addition, the rapid clearance
through the kidneys accelerates the acquisition of imageswith sufﬁcient
TBR, as demonstrated in our previous studies in which a nanobody was
compared to an antibody for optical molecular imaging [30,31]. The
nanobodies that we used for PDT, i.e. the monovalent 7D12 [31,33]
and the biparatopic 7D12-9G8 [34], speciﬁcally targeted the epidermal
growth factor receptor (EGFR). With more than 83% of all head and
neck squamous cell carcinomas overexpressing EGFR [35], it serves as
a promising target in head and neck cancer patients. In fact, increased
levels of EGFR are associated with poor prognosis by locoregional failure
and decreased survival [36]. The PS thatwe conjugated to the nanobodies
was IRDye700DX, which is a water-soluble silicon-phthalocyanine deriv-
ative, that has a strong absorption band in the near-infrared region of the
spectrum (690 nm) and is also traceable through optical imaging [15,37].
Our previous studies showed that, in vitro, the nanobody–PS conjugates
(i.e. 7D12–PS and 7D12-9G8–PS) bound speciﬁcally to EGFR, allowing
the distinction of cell lines with different expression levels of EGFR. Nota-
bly, the conjugates speciﬁcally induced cell death of EGFR overexpressing
cells in low nanomolar concentrations. Importantly, the biparatopic con-
jugate (i.e. 7D12-9G8–PS) was more toxic, as it could deliver more PSintracellularly [25], via the clustering induced endocytosis of EGFR [38].
These encouraging results have stimulated further investigation of these
conjugates in an in vivo setting.
The aim of the present study is to investigate the therapeutic poten-
tial of nanobody–PS conjugates for targeted PDT, i.e. to determine
whether these conjugates are capable of inducing selective tumor cell
death in vivo, in a pre-clinical head and neck tumor model. First, the
nanobody–PS conjugates are characterized for their speciﬁcity and pho-
totoxicity in vitro employing the EGFR overexpressing oral squamous
cell carcinoma cell line OSC-19-luc2-cGFP (OSC). Subsequently, this
cell line is grown as an orthotopic model in the tongue of mice to
allow pre-clinical evaluation through histological analysis post-PDT. As
a reference or positive control, and for validation of themodel and anal-
ysis procedure employed in this feasibility study, Cetuximab–PS was
employed as Mitsunaga et al. [15] have described the use of their
mAb–PS conjugates. To determine the best time point for illumination
after intravenous injection of the nanobody–PS conjugates, quantitative
ﬂuorescence spectroscopy is employed. This is a method that has been
developedwithin our group and is currently being evaluated in the clin-
ic for guiding PDT applications, as it provides insights in the pharmaco-
kinetics (through local distribution) of the PS. Thereafter, PDT is applied
in this orthotopic tumor model and the efﬁcacy is evaluated in vivo by
histological analysis. Our data show that nanobody–PS conjugates are
selective and able to induce speciﬁc tumor cell death in a pre-clinical
model of head and neck cancer.
2. Materials and methods
2.1. Nanobodies and PS conjugation
Nanobodies 7D12, R2, and 7D12-9G8 were produced as described
previously, i.e. His-tagged nanobodies were produced in E. coli and
puriﬁed from the periplasmic space by TALON afﬁnity puriﬁcation [31,
34]. The nanobody 7D12 binds to the domain III of the EGFR, preventing
EGF binding to the receptor [39]. The biparatopic nanobody7D12-9G8 is
composed of two nanobodies that bind to different epitopes on EGFR
and that cannot bind simultaneously to the same receptor, therefore
being able to create clusters of receptors [39]. The irrelevant nanobody
R2 is employed as a control and was speciﬁcally selected to bind to
the azo dye Reactive Red 6 [40,41]. The photosensitizer IRDye700DX
(here named PS) was purchased from LI-COR (LI-COR Biosciences,
Lincoln, Nebraska) as an N-hydroxysuccinimidine (NHS) ester. Conju-
gation of the PS to the nanobodies was performed as described in
Heukers et al. [25], except that the molar ratio for conjugation was 1
to 4 for 7D12–PS and 1 to 2 for R2–PS and 7D12-9G8–PS. After 2 h at
room temperature, the conjugates were separated from free PS by size
exclusion chromatography using Zebra Spin Desalting columns
(Thermo Fisher Scientiﬁc, Perbio Science Nederland, Etten-Leur,
The Netherlands), in three sequential steps. The degree of conjuga-
tion (DOC) was determined as recommended by the provider, by
measuring the absorbance at 280 nmand689nmusing aNanoDrop spec-
trophotometer (NanoDrop Technologies, Wilmington, Delaware, USA).
Purity and integrity of the nanobody–PS conjugates were determined
by molecular size separation through SDS-PAGE using 15% gels. Immedi-
ately after running the gels, these were imaged on an Odyssey Infrared
scanner (LI-COR Biosciences) using the 700 nm channel to detect PS ﬂuo-
rescence. Thereafter, Coomassie Blue staining was performed and detect-
ed in the same way as the PS. Cetuximab–PS was used as a reference or
positive control in this study andwas obtained as described byMitsunaga
et al. [15] for panitumumab.
2.2. Cell lines
Three human cell lines with different EGFR expressions were used.
The well differentiated squamous cell carcinoma of the tongue OSC-
19-luc2-cGFP (high EGFR overexpression) was cultured in Dulbecco's
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4.5 g D-glucose/L, 110 mg sodium pyruvate/L, 580 mg L-glutamine/L
supplemented with 10% fetal bovine serum (FCS; Lonza, Basel, Swiss),
400 IU/mL penicillin, 100 μg/mL streptomycin (Invitrogen) 1×Minimal
Essential Medium (MEM) non-essential amino acids solution and 1×
MEM vitamin solution (Invitrogen) [42]. The human cervical cancer
cell line HeLa (intermediate EGFR expression) was cultured in DMEM
(Gibco, Invitrogen, United Kingdom) supplemented with 8% FCS (v/v),
100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine
(PAA, Germany) [25]. The human colorectal cancer cell line SW620
(low EGFR) was cultured in Leibovitz's L-15 medium (Invitrogen) con-
taining 300 mg L-tlutamine/L supplemented with 10% FetalClone II
(Hyclone, Logan, UT), 100 IU/mL penicillin, 100 μg/mL streptomycin
(Invitrogen) and 20 mM HEPES (Invitrogen) [42]. All cell lines were
grown in a humidiﬁed incubator at 37 °C and 5% CO2 andwere regularly
checked forMycoplasma infection by polymerase chain reaction.
2.3. Cell binding assay
A total of 8000 cells were seeded per well of a 96-wells plate (Nunc,
Roskilde, Denmark) and allowed to adhere overnight. For the afﬁnity
determination, plates were placed at 4 °C and cells were washed with
cold binding medium (1% BSA and 25 mM HEPES in DMEM without
phenol red, pH 7.2). Subsequently, cells were incubated with a concen-
tration range of nanobody–PS conjugates in binding medium for 2 h at
4 °C. Thereafter, cells were washed twice with cold binding medium
and bound conjugates were detected though ﬂuorescence imaging of
the PS with the Odyssey Infrared scanner, using the 700 nm channel.
Fluorescence intensities were plotted (in triplicate ± SEM) versus the
concentrations. The resulting saturation curves were used to determine
the apparent afﬁnity (kD) of the nanobody–PS conjugates, using the
GraphPad Prism 5.02 software for Windows (GraphPad Software, San
Diego, CA), and one-site speciﬁc binding, non-linear regression proto-
col. Experiments were repeated at least twice. For evaluation of the
binding speciﬁcity by ﬂuorescence microsocpy, cells were incubated
with 25 nMof nanobody–PS as described above, followed by twowash-
ing steps and incubation with calcein AM (0.5 μg/ml, Invitrogen) for de-
tection of cells. This calcein incubationwas not performedwith OSC cell
line as this one is GFP positive and thus already detectable through ﬂuo-
rescencemicroscopy. Imagingwas performedwith an EVOSMicroscope
(Advanced Microscopy Group, AMG, Thermo Fischer Scientiﬁc)
equipped with 10× objective (Plan Fluor, 10×, NA 0.3, Air and working
distance 8.3 mm, AMG) and the following LED-based ﬂuorescence light
cubes: GFP (Cat. no. 12-563-470) and Cy5 (for PS detection, Cat. no. 12-
563-475) (fromWestover Scientiﬁc Inc., AMG). Overlays of the separate
imageswere also generatedwith the EVOSMicroscope software (AMG).
2.4. Steady-state ﬂuorescence and absorption measurements
The ﬂuorescence quantum yields (ΦF) of the nanobody/antibody
conjugates were determined using a relative method in PBS (pH 7.4)
[43] using Chlorin e6 (Ce6) in the same buffer as a reference. At
pH 7.4 the ﬂuorescence quantum yield of Ce6 is 0.18 [44,45]. The ab-
sorption spectrum of Ce6 and conjugates (concentration 1 × 10−6 M)
was recorded in Shimadzu spectrophotometer (UV-2101 PC, Duisburg,
Germany). The ﬂuorescence emission of PS was recorded in a Perkin-
Elmer spectroﬂuorometer (LS 50B, Massachusetts, USA). Ce6 and conju-
gates ﬂuorescence spectra were acquired under 630 nm and 660 nm
excitation respectively at an OD lower than 0.1. Calculations ofΦF was ac-
companied by careful consideration of the differences in photon number
at different wavelengths.
2.5. Singlet oxygen quantum yield measurements
Photo-oxidation of Singlet Oxygen Sensor Green Reagent (SOSGR)
(Molecular Probes, NL) was used to determine the singlet oxygenformation by the nanobody–PS conjugates. This reagent was used
because of its high selectivity for singlet oxygen and low sensitivity to hy-
droxyl radicals/superoxides [46]. Stock solution of SOSGR (5 mM) was
prepared in methanol. The ﬁnal concentration of SOSGR within the PS
solution in PBS pH 7.4 was 1 μM. Solutions of PS and nanobody–PS or
antibody–PS conjugates were prepared in PBS pH 7.4. The concentration
of PSwere adjusted so that all absorb the same number of photonswithin
the irradiated region (O.D.=0.014 at theλirr.= 660 nm(Spectra Physics,
NL). Datawas acquired in quartz cuvettes in aerobic conditions using stir-
ring under uniform,measured ﬂuence rate at 5mW/cm2. At intervals, the
cuvette was removed from magnetic stirrer and absorption and ﬂuores-
cence emission spectrum (λexc = 405 nm) acquired. The singlet oxygen
quantum yields (ΦD) of conjugates in PBS were determined in duplicate
by a relative method [47] with a ΦD = 0.64 of Ce6 in the PBS at pH 7.4
as reference [48].
2.6. In vitro PDT
One day after seeding 8000 cells per well of 96-wells plates
(Greiner Bio-One, Alphen a/d Rijn, The Netherlands), cells are
washed once with PDT medium (DMEM without phenol red supple-
mented with 8% FCS (v/v), 100 U/ml penicillin, 100 μg/ml streptomycin,
and 2 mM L-glutamine). Then, a dilution range of nanobody–PS conju-
gates was added to the cells and incubated for 30 min at 37 °C. After the
incubation (also referred to as pulse), cells were washed twice with PDT
medium. Immediately after, the ﬂuorescence intensity of the conjugates
bound to and/or internalized by the cells was detected with the Odyssey
scanner and the cells were illuminated immediately after. Plates were il-
luminated with ~4 mW/cm2 ﬂuence rate (measured with an Orion
Laser power/energy monitor, Ophir Optronics LTD, Jerusalem, Israel), for
a total dose of 10 J/cm2, using a device consisting of 96 LED lamps
(670 ± 10 nm, 1 LED per well) described in [49,50]. After illumination,
cells were placed back into the incubator, unless mentioned otherwise.
In all experiments, a number of wells were covered during illumination
as internal negative control. Experiments were repeated at least twice.
2.7. Cell viability assays
After overnight incubation of the cells treated as described above,
cells were incubated with the Alamar Blue reagent, according to the
manufacturer's protocol (AbD Serotec, Oxford, United Kingdom),
i.e. 10 μl of Alamar Blue was added into each well and mixed with the
100 μl of medium present in the wells. After an incubation of 1 h at
37 °C, ﬂuorescence intensity was measured on a FluoStar Optima ﬂuo-
rescent plate reader (BMG Labtech GmbH, Ortenberg, Germany). Values
of ﬂuorescence intensities obtained fromwells only containingmedium
and Alamar bluewere taken as background, while wells containing cells
that were covered during illumination and that were not treated with
nanobody–PS conjugates were set to 100% cell viability. Results are
expressed as cell viability in percentage (%), thus relatively to the un-
treated cells, and the half maximal inhibitory concentration (IC50) are
determined using the GraphPad Prism 5.02 software.
2.8. Co-culture assay
A mixture consisting of 50% of HeLa and 50% of OSC cell lines was
seeded in 96-wells plates (Greiner), pulsed with 25 nM of nanobody–
PS and followed by 10 J/cm2 of light dose. After overnight incubation
(~16h), dead cellswere distinguished from living cells by propidium io-
dide (1 μg/ml, Invitrogen) and calcein AM (0.5 μg/ml, Invitrogen) stain-
ing, according to the manufacturers' protocol. Cells were imaged with
an EVOS Microscope equipped with 10× objective and the following
LED-based ﬂuorescence light cubes: GFP for calcein AM and RFP (Cat.
no. 12-563-471) for propidium iodide. Phase contrast images were
also taken. Overlays of the separate images were generated with the
EVOS Microscope software.
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Nude Balb/c female mice (Charles River laboratories, l'Arbresle,
France), aged 4–6 weeks, were housed in individually ventilated cages
and provided with food and sterilized water ad libitum. Animal experi-
ments were approved by the local animal welfare committee of the
Leiden University Medical Center. Orthotopic tongue tumors were
submucosally induced in the tip of the tongue through injection of
40,000 OSC-19-luc2-cGFP cells, in suspension in 20 μl PBS. General
health was monitored twice a week by weight measurements and
inspection of the tongue. Tumor growth was monitored twice a week
by bioluminescence (BLI) measurements and visual inspection of the
tongue. Mice were sacriﬁced by injection of high-doses ketamine/
xylazine.
2.10. Quantitative ﬂuorescence spectroscopy
Quantitative ﬂuorescence spectroscopy, which fully corrects for the
differences in tissue optical properties, was performed as described
previously [51]. White light reﬂectance and ﬂuorescence spectra were
acquired using a single probe that contained two ﬁbers of 0.4 and
0.8 mm. The 0.8 mm ﬁber was used for both ﬂuorescence and reﬂec-
tance spectroscopy while the 0.4 mm ﬁber was used to perform reﬂec-
tance spectroscopy. The end of the ﬁber probe in contact with the tissue
waspolished to an angle of 15° tominimize the collection of specular re-
ﬂection. To obtain a reﬂectance spectrum, light from a tungsten halogen
lamp was directed on the tissue through a probe containing 2 single ﬁ-
bers with diameters of 0.4 and 0.8 mm. This choice of ﬁber diameters
was dictated by the intention to optically sample a representative pro-
portion of the tumor and normal tissue under interrogation. The photon
path length and therefore the sampling volume is on the order of the
ﬁber diameter which means that approximately 1/3 of the tumor vol-
ume is interrogated by the smallest ﬁber diameter. After these sequen-
tial reﬂectance measurements, a single ﬁber ﬂuorescence spectroscopy
(SFF) spectrum was acquired using the 0.8 mm ﬁber and 660 nm laser
light. This wavelength was chosen to optimally separate IRDye700DX
(PS) ﬂuorescence from background autoﬂuorescence. The reﬂectance
and ﬂuorescence spectra were detected by three spectrometers, one
for each ﬁber to measure reﬂectance and one to measure ﬂuorescence
where a 675 nm notch ﬁlter was used to block scattered excitation
light. The spectrometers, light sources and shutters were controlled by
a custom made LabView program (National Instruments LabView 7.1)
on a notebook computer. A single combined multi-diameter optical
ﬁber (MDSFR)/SFF measurement took approximately 3 s. The ﬁber
probe was removed from the tissue and replaced to perform repeated
measurements. Three spectra were acquired from each tissue type,
and the average and standard deviation of these measurements were
reported.
2.10.1. Data analysis
To calculate the intrinsic ﬂuorescence, the raw ﬂuorescence signals
were corrected for the effects of absorption and scattering using the opti-
cal properties obtained from the MDSFR reﬂectance spectra. A detailed
mathematical description of the recovery of the tissue optical properties
from an MDSFR spectrum and their use in determining the intrinsic SFF
from a raw ﬂuorescence spectrum has been described previously [52].
The result of this analysis is a calibrated, corrected ﬂuorescence spectrum
expressed as the wavelength-dependent intrinsic ﬂuorescence, where
Q(l)μ f is the quantum efﬁciency of the ﬂuorophore at each emission
wavelength. This spectrum is then integrated over the emission band-
width of the ﬂuorophore IRDye700DX (PS) to yield the intrinsic ﬂuores-
cence Q · μ fa,x where Q is now the ﬂuorescence quantum yield of the PS.
2.10.2. Fluorescence spectral analysis
The ﬂuorescence spectra, corrected for the inﬂuence of tissue optical
properties, were then analyzed to determine the contribution from thetissue autoﬂuorescence, and that from PS. A skewed Gaussian was used
to ﬁt the autoﬂuorescence while the basis spectra for PS conjugated to
each antibody/nanobody were isolated from an average of representa-
tive in-vivo spectra after subtraction of the autoﬂuorescence [53]. We
note that the width and peak of PS ﬂuorescence was slightly different
for each antibody/nanobody conjugate.
2.10.3. Calibration of the MDSFR/SFF system
Before each set ofmeasurements a careful calibration procedurewas
performed as described previously [54] consisting of an integrating
sphere calibration, a measurement of a calibrated light source, and
measurements in water in a dark container and in a liquid phantom
containing 1.32% Intralipid with a known reduced scattering coefﬁcient
(μs′ at 800 nm= 1.2 mm−1). This procedure accounts for variations in
the output powers of the light sources and the spectral transmission and
sensitivity of the system.
2.10.4. Quantitative ﬂuorescence spectroscopy in vivo
When OSC tumors were visible by the human eye and the BLI signal
ranged between 5 × 109 and 1 × 1010 relative light units (RLU), mice
were randomly divided into three groups and received an intraveneous
injection of 200 μg of 7D12–PS, 7D12-9G8–PS, or R2–PS, eachmouse re-
ceiving approximately 6 nmol of PS to allow comparison. Quantitative
ﬂuorescence spectroscopy measurements were performed 0.5, 1, 2, 4,
6, 8 and 24 h after injection of the conjugates. Cetuximab–PS was
employed as other mAb–PS were described in [15] (i.e. 300 μg and
also approximately 6 nmol of PS per mouse) and measurements were
only performed at 24 h p.i., which corresponded to the selected illumi-
nation time point.
2.11. Tumor speciﬁcity and distribution
Tumor speciﬁcity of 7D12–PS and 7D12-9G8–PS was explored by
optical imaging in vivo and ﬂuorescence imaging of tissue sections. At
1 h after injection of 7D12–PS, 7D12-9G8–PS and R2–PS (200 μg),
mice were imaged (n = 2) with the Pearl imaging system (LI-COR),
while kept under isoﬂurane anesthesia.
In parallel, othermice injectedwith each of the nanobody–PS conju-
gates (n= 1) had their tongues resected, ﬁxed overnight in 4% formalin
and embedded in parafﬁn blocks. Tissue was sectioned at 10 μm and
ﬂuorescence imaging was performed using the Odyssey. All images
were acquired using the same settings. Further, sectionswere processed
for hematoxylin and eosin (H&E) staining.
2.12. Photodynamic therapy
When OSC-19-luc2-cGFP tumors were visible by the human eye and
the BLI signal ranged between 5 × 109 and 1 × 1010 relative light units
(RLU),mice (n=4per group)were randomly divided into three groups
and received an intraveneous injection of 200 μg 7D12–PS, 7D12-9G8–
PS, R2–PS, or 300 μg cetuximab–PS. Based on the quantitative ﬂuores-
cence spectroscopy measurements, 1 h post-injection (p.i.) was chosen
to apply the light. Thus at this time after nanobody–PS administration,
or 24 h p.i. of cetuximab–PS injection, mice received painkillers, were
put under isoﬂurane anesthesia, and their tumors were then illuminat-
ed using a 690 nm diode laser (Modulight, Tampere, Finland). The
power at the end of the optic ﬁber was calibrated with a power meter
(Gigahertz optic, Turkenfeld, Germany). Light was delivered via a
600 μmoptic ﬁberwith a ﬂuence rate of 50mW/cm2 and a homogenous
treatment area with the largest diameter of the tumor was used. The
exposure time was adjusted to obtain a ﬂuence of 100 J/cm2. Mice
were sacriﬁced 24 h after illumination, tongues were collected and
frozen on dry ice for subsequent processing for histological analysis of
tissue damage.
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To assess whether nanobody-targeted PDT is capable of inducing
selective tumor cell death in vivo, and using antibody-targeted PDT as
a positive control, tongues of mice were collected 24 h after application
of light for PDT. Thereafter, tongues were sectioned and processed for
H&E staining and for CD31 staining of blood vessels. Brieﬂy, for the
CD31 staining, sections were subjected to 10 mM tris/EDTA at 96 °C
for 20 min. Thereafter, endogene peroxidase was blocked with a
solution of 3% hydrogen peroxide. Blocking of aspeciﬁc staining was
performed with a solution of 5% low fat milk, for 30 min. Then, the pri-
mary antibody rabbit anti-CD31 (Abcam, Cambridge, UK) and the sec-
ondary antibody goat-anti rabbit biotin (Dako, Heverlee, Belgium)
were employed, followed by streptavidin-HRP (Southern Biotech, Bir-
mingham, AL) and the ﬁnal development of the brown color with
DAB, and counterstained with hematoxylin. Pictures were taken with
an Olympus microscope equipped with a 4×, 10× or 20× objectives.
Two independent researchers scored thedamage onH&E tissue sections
in percentage (%) of necrosis and scored phototoxicity of normal epithe-
lium, muscle cells, and endothelium (blood vessels), as well as edema,
from 0 or 1+ to 3+ by observation of the tumor, and of the blood ves-
sels or themuscle cells, either in close proximity or distant to the tumor.
The CD31 staining was employed to score the damage of blood vessels
in the tumor area by absence of the brown color. An experienced pathol-
ogist was the ﬁrst observer and was responsible for the training of the
second observer. At least 3 sections at different depths were analyzed
per tumor. The second observer made use of the Image J software to
determine % of necrosis, by drawing regions of necrosis and comparing
to the overall region of the tumor. At the end, a consensus was reached
on the ﬁnal score.
2.14. Statistical analysis
Data was analyzed using the GraphPad Prism 5.02 software for
Windows (GraphPad Software, San Diego, CA). To compare responses to
PDT treatment in vitro, analysis of signiﬁcance was performed through
unpaired t-tests. Intrinsic ﬂuorescence values are reported as mean and
standard deviation. Statistical analysis of spectroscopy was performed
through a two way ANOVA with the Bonferroni correction. As for the
effect in vivo, analysis of signiﬁcance was performed through Mann–
Whitney test because of the non-normal distribution of the data. In all
cases, p b 0.05 was considered signiﬁcant.
3. Results and discussion
Targeted PDT aims to increase tumor speciﬁcity of the PS, in order to
enhance the therapeutic effect and spare surrounding normal tissue. In
this study, we evaluate the recently introduced nanobody–PS conju-
gates for their potential to induce speciﬁc tumor cell death in vivo.
3.1. Characterization and EGFR-speciﬁc binding of the nanobody–PS
conjugates
The nanobodies targeting EGFR used in this study are the monova-
lent 7D12 [31,33] and the internalizing, biparatopic 7D12-9G8 [34]. In
addition, the irrelevant nanobody R2 [40,41] is used as a negative con-
trol. These nanobodies were conjugated to the PS (IRDye700DX) via
random NHS-mediated coupling to lysine amino acids, similarly to the
previous study [25]. After removal of unconjugated PS, SDS-PAGE was
used to verify the conjugation. Themolecular weights of the ﬂuorescent
nanobody–PS conjugates, as detected by ﬂuorescence imaging (top gel,
red bands, Fig. 1A), were similar to those of the nanobodies, as demon-
strated by the post-Coomassie Blue stained SDS-PAGE gel (bottom gel,
black bands, Fig. 1A). Furthermore, very little unconjugated PS was
detectable at the front of the gel (Fig. 1A), which rendered the conju-
gates suitable for both in vitro and in vivo studies. The PS-to-proteinmolar ratios (or degree of conjugation, DOC) of 7D12–PS, 7D12-9G8–
PS and R2–PS after random conjugation were on average 0.5, 1.0 and
0.5, respectively. Compared to our previous study, these are different
ratios or DOC, except for 7D12–PS. In fact, 0.5 is the highest DOC this
nanobody–PS can have while maintaining its low nanomolar binding af-
ﬁnity. For the negative control R2–PS, we chose to use the same DOC as
for 7D12–PS (i.e. 0.5, instead of 1.0). To enable the comparison of the ther-
apeutic potential in vivo, theDOCof 7D12-9G8–PSwas also decreased and
used as twice the DOC of 7D12–PS (i.e. 1.0, instead of 1.5). This particular
choice wasmade aiming at themost effective delivery of the drug, i.e. the
PS, by the least amount of carrier needed, i.e. protein, in a manner that
would allow normalization of PS dose administered in vivo. Thus, with
the selected DOCs, the in vivo administration of equal amounts of protein
(i.e. nanobody, in micrograms), result in the administration of equal
molar amounts of PS, allowing a better comparison of the therapeutic po-
tential. These two nanobody formats (i.e. 7D12–PS and 7D12-9G8–PS)
are two independent carriers used for PS delivery, which are here investi-
gated side-by-side, as it is difﬁcult to anticipate which format is the most
promising for in vivo application.
Next, the speciﬁcity of 7D12–PS and 7D12-9G8–PS for binding to
EGFR was demonstrated. For that, besides the human oral squamous
cell carcinoma cell line OSC (Fig. 1B), two human control cell lines
were employed: the cervical cancer cell line HeLa and the colon cancer
cell line SW620 (Fig. 1C). These three cell lines express high, intermediate
(or normal), and very low levels of EGFR, respectively. Binding assays
were performed at 4 °C to solely explore the binding of conjugates to
EGFR. Fluorescence intensities of the bound conjugates correlated well
with the level of EGFR expression, i.e. OSC N HeLa N SW620. Moreover,
the approximately 2-fold difference in ﬂuorescence intensity observed
between the two EGFR targeted nanobody–PS conjugates correlated
well with the difference in DOC. Binding afﬁnities of 7D12–PS and
7D12-9G8–PS to high EGFR expressing OSC cells were 1.9 ± 0.4 nM and
1.0 ± 0.1 nM, respectively; and to intermediate EGFR expressing HeLa
cells were 0.7± 0.3 nM and 0.5± 0.07 nM, respectively. Hardly any ﬂuo-
rescence, and thus binding, was observed for 7D12–PS and 7D12-9G8–PS
to low EGFR expressing SW620 cells, and for R2–PS and PS to any of the
cell lines. To emphasize the speciﬁc binding of the nanobody–PS conju-
gates to EGFR, ﬂuorescence microscopy was performed (Fig. 1D).
Among the three cell lines, binding of 7D12–PS and 7D12-9G8–PS was
mainly observed in the high EGFR expressing OSC cells (Fig. 1D). As for
R2–PS and PS, no ﬂuorescence was observed in any of the three cell lines.
Overall, comparable to our previous study, both 7D12–PS and 7D12-
9G8–PS target EGFR speciﬁcally. Importantly, this water-soluble PS
(IRDye700DX) has no cell binding capacity, unless it is conjugated to
the EGFR targeted nanobodies. These facts together could guarantee
tumor-speciﬁc PDT.3.2. Singlet oxygen quantum yield and in vitro efﬁcacy of nanobody–PS
conjugates
To determine the relative potency of these nanobody–PS conjugates,
singlet oxygen quantum yields (ϕΔ) were measured in test tubes. For
that, ﬁrst, ﬂuorescence quantum yields were determined using a rela-
tive method in PBS and Chlorin e6 as a reference. The ﬂuorescence
quantum yields of PS, 7D12–PS and 7D12-9G8–PS were 0.15 ± 0.03,
0.14± 0.03 and 0.16± 0.03, respectively. Interestingly, the determined
ϕΔ differed signiﬁcantly between photosensitizer and conjugates: for PS
it was determined to be 0.19 ± 0.06, for 7D12–PS 0.25 ± 0.06, and for
7D12-9G8–PS 0.42± 0.07. Previous studies have also documented var-
iations in ﬂuorescence and singlet oxygen quantum yields for free PS
and conjugates with different DOC [55]. The differences in ϕΔ, for the
two nanobody–PS conjugates, may be related to variations in amino
acids to which the PS is conjugated, thus affecting the environment
surrounding PS molecules. Although the efﬁcient generation of singlet
oxygen is an important factor in the induction of phototoxic effects,
Fig. 1. Purity and speciﬁcity of nanobody–PS conjugates. (A) Nanobodies and the respective nanobody–PS conjugates are separated by SDS-PAGE, with the following order (numbered
1–6): R2, R2–PS, 7D12, 7D12–PS, 7D12-9G8, and 7D12-9G8–PS. Prior to the Coomassie stain, the ﬂuorescence of the PS is detected (depicted in red, top gel); after the Coomassie stain,
the proteins are visualized (depicted in black, bottom gel). (B) Fluorescence intensities of cell bound conjugates are plotted after incubation of OSC cells or (C) the control cell lines
HeLa and SW620 with varying concentrations of the EGFR targeted conjugates 7D12–PS and 7D12-9G8–PS, or the controls R2–PS and PS. EGFR expression levels:
OSC N HeLa N SW620. (D) Fluorescent microscopy depicting the ﬂuorescence of the nanobody–PS bound to cells (in white, left panels) and that (in red, right panels) overlayed with
either GFP (OSC cell line) or calcein staining (HeLa, SW620) for cell visualization (in green, right panels).
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also inﬂuence signiﬁcantly the overall therapeutic effect.
The phototoxicity of different concentrations of these conjugates
was assessed in vitro following an incubation time of 30 min. This time
period was based on previous work, in which we reported saturable
binding of nanobody–PS conjugates after 30 min of incubation [25].
The EGFR targeted nanobody–PS conjugate 7D12-9G8–PS showed to
be a very potent PDT agent on OSC cells with an IC50 value of 2.2 ±
0.97 nM (Fig. 2A). As for 7D12–PS, cell viability was decreased by
32.3% at 50 nM, suggesting an IC50 higher than 50 nM, though likely
below themicromolar range. No reduction of cell viabilitywas observed
after illumination of cells incubated with R2–PS or PS alone, indicating
the need of speciﬁc targeting to induce cell damage (Fig. 2A).
The difference in phototoxicity between 7D12–PS and 7D12-9G8–PS
in vitro is larger than the difference in ﬂuorescence intensity of the con-
jugates associatedwith the cells just before illumination (Supplementa-
ry Material, Fig. S1). This could partially be explained by the higher
singlet oxygen quantum yield of 7D12-9G8–PS. Furthermore, several
studies pointed to an intracellular localization of the PS as important
to increase the phototoxicity of mAbs–PS [56–58]. In fact, aswe showed
in our previous study, more 7D12-9G8–PS is delivered intracellularly
compared to 7D12–PS,which has been described to be via clustering in-
duced endocytosis of EGFR [25]. Thus, both aspects are likely to explain
the higher potency of 7D12-9G8–PS in vitro. Our previous study showed
even lower IC50 values for 7D12–PS and 7D12-9G8–PS, though that canFig. 2.Nanobody–PS are phototoxic to EGFR overexpressing cells. Phototoxicity of nanobody–PS
of cell viability after a 10 J/cm2 light dose. Data depicted as means ± SEM. (C) Fluorescence an
conjugates or the controls R2–PS and PS. Left panel depicts PS ﬂuorescence, middle panel propi
phase contrast to visualize cells. Cells can be differentiated by morphology and ﬂuorescence ofbe partly justiﬁed by a lowerDOC for 7D12-9G8–PS in the current study,
and also by the different EGFR expression levels of the cell lines employed.
In our previous study, A431 and 14C cell lineswere employedwhich have
higher EGFR expression than the OSC cells.
Here, to conﬁrm that the phototoxicity is indeed dependent on the
EGFR level, toxicity was also assessed on cell lines with different EGFR
expression levels (Fig. 2B, i.e. HeLa and SW620), and indeed the photo-
toxicity was lower than the values obtained with OSC cells, which relat-
ed to the extent of conjugate bound to cells (Supplementary Material,
Fig. S1), and correlated to the EGFR expression as demonstrated in
Fig. 1B and C. The IC50 on HeLa cells was 33.5 ± 1.4 nM for 7D12-
9G8–PS, while 7D12–PS induced almost no effect in the concentration
range here tested (i.e. highest concentration 50 nM). These are signiﬁ-
cantly lower toxicities than observed in high EGFR expressing OSC
cells. No IC50 could be calculated for SW620 cells indicating the absence
of cell damage on low EGFR expressing cells (Fig. 2B).
Co-culture experiments were performed to assess the selectivity of
these nanobody–PS conjugates toward OSC cells overexpressing EGFR,
among intermediate EGFR expressing HeLa cells (Fig. 2C). In these co-
cultures, HeLa and OSC cells could be distinguished by the differences
in morphology and GFP ﬂuorescence imaging of cGFP transfected OSC
cells (i.e. OSC-19-luc2-cGFP). 7D12–PS and 7D12-9G8–PS induced
phototoxicity only to OSC cells, as indicated by the propidium iodide
staining (indicative of dead cells, Fig. 2C) that coincides with GFP
ﬂuorescence. Also here, 7D12-9G8–PS showed to be more toxic thanconjugates and controls in (A) OSC, (B) HeLa and SW620 cells presented as percentage (%)
d phase contrast images of co-cultures of HeLa and OSC cells after PDT with nanobody–PS
dium iodide (PI) to identify dead cells, and right panel the overlay of PI with both GFP and
the GFP (green) positive OSC cells.
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phototoxicity was observed under the same conditions on HeLa cells
(See Supplementary Material for similar treatment on these two cell
lines separately, Fig. S2).
3.3. Pharmacokinetics and macroscopic localization of nanobody–PS
conjugates
To investigate the selectivity and potency of these nanobody–PS
conjugates in a pre-clinical model of head and neck cancer, the OSC
cell line was inoculated and grown orthotopically in tongues of nude
mice. Being the ﬁrst pre-clinical study,we have decided to use a reference
for validation of the procedure here employed: we used Cetuximab–PS as
Mitsunaga et al. [15] have described the use of their mAb–PS conjugates,
i.e. with a DOC of 3.0 and injecting a dose of 300 μg per mouse, which are
equivalent to approximately 6 nmol of PS. With these particular condi-
tions, we expected to induce tumor cell death and subsequently validate
the procedure selected for analysis. Based on the selected DOC of the dif-
ferent nanobody–PS, the dose of protein to be injected was calculated so
that it was normalized for the amount of drug carried, i.e. PS.
For an effective PDT without damage to normal tissue, light should
be applied locally at the most favorable time point post-injection (p.i.)
of the nanobody–PS conjugates. This is when the highest dose of PS is
located at the tumor, and the lowest dose in the surrounding tissues.
In practice, this generally corresponds to a balance between the dose
of PS at the tumor and a sufﬁcient tumor-to-background ratio (TBR).
As the nanobody–PS conjugates are traceable through optical imaging,
wide ﬁeld ﬂuorescence imaging gives insights into their tumor speciﬁc-
ity and distribution in vivo. However, the differences in optical proper-
ties of different tissues greatly inﬂuence the number of collected
ﬂuorescent photons. Alternatively, determining the intrinsic ﬂuores-
cence enables a quantitative comparison of ﬂuorescence's pharmacoki-
netics locally in tissues with different and/or varying optical properties
(such as in tumor, normal tongue, and skin). Our group has been inves-
tigating the use of empirical modeling and point reﬂectance spectrosco-
py with multi-diameter optical ﬁbers (MDSFR) combined with single
ﬁber ﬂuorescence spectroscopy (SFF) to measure the tissue optical
properties μa, μ′s, and thereby recovering the intrinsic ﬂuorescence
from the interrogated volume [52]. This approach is particularly impor-
tant when the optical properties of tumor and normal tissue are known
to be signiﬁcantly different [51]. Using this method, the quantitative
ﬂuorescence pharmacokinetics were assessed for the PS (IRDye700DX)
in each conjugate. The intrinsic ﬂuorescence reported in this study,
deﬁned as Qfμaf, is the product of the ﬂuorescence quantum yield of
the PS and its absorption coefﬁcient at 660 nm.While reliable estimates
of Qf and the in vivo extinction spectrum of the PS would allow for the
quantitative determination of its concentration in vivo, we considered
it sufﬁcient for this study to determine the intrinsic ﬂuorescence.
No signiﬁcant differenceswere observed in normal tongue tissue be-
tween all conjugates. At all time points, signiﬁcantly less R2–PS was
present in the tumor compared to 7D12–PS and 7D12-9G8–PS
(p b 0.05 for all time point) (Fig. 3A). For 7D12–PS, more conjugate
was present in the tumor compared to that in normal tongue tissue
and skin, proving tumor speciﬁcity in vivo. Differences were statistically
signiﬁcant (p b 0,05) at time-point 0.5, 1, 6 and 24 h p.i. The maximum
amount of 7D12–PS in the tumor was observed already at 30 min p.i.,
after which it slowly decreased, correlating with our previous imaging
study [31], and possibly related to the unbinding of non-internalized
conjugates. However, a relatively high value of ﬂuorescence was also
present in normal tongue tissue at 30min p.i. At 1 h p.i. the ﬂuorescence
at the normal tongue tissue decreased slightly and a TBR of 1.8 ± 0.3
was obtained. Although at a later time point the TBR increased, such
as to a value of 16.1 ± 4.5 at 24 h p.i. (Fig. 3B), the total ﬂuorescence
of 7D12–PS in the tumor at 24 h p.i. had already decreased 42% from
the intrinsic ﬂuorescence at 1 h p.i. Differences in TBR of 7D12–PS, com-
pared to R2–PS, were statistically signiﬁcant at 24 h p.i (p b 0.0001).Similar results were obtained for 7D12-9G8–PS, showing tumor
speciﬁcity in vivo as signiﬁcantly more conjugate was present in the
tumor compared to that in normal tongue tissue and skin (p b 0.05 for
all time points, except for 8 h p.i.). Unlike 7D12–PS, the highest intrinsic
ﬂuorescence at the tumor was observed for a longer period, i.e. during
the ﬁrst 4 h p.i., which is possibly related to a more pronounced inter-
nalization and less unbinding of non-internalized conjugate. Already
at 1 h p.i. a TBR of 3.8 ± 0.5 was obtained. Also in this case, higher
TBR could be obtained at later time points, such as 30.8 ± 0.9 at 24 h
p.i. The differences in TBR of 7D12-9G8–PS, compared to R2–PS, were
statistically signiﬁcantly at both 1 and 24 h p.i. (p = 0.0024 and
p b 0.0001, respectively). However 24 h p.i. the intrinsic ﬂuorescence
had also in this case decreased 39%, compared to 1 h after the injection.
One could expect that high TBRs are needed to spare normal tissue,
and to enable accurate tumor detection with ﬂuorescence imaging (in
the setting of image-guided PDT). Nevertheless, in principle, the actual
amount of PS in the tissue predominantly determines the actual photo-
toxic effect. Therefore, in order to maximize the concentration of PS
while retaining a suitable TBR, we decided to subsequently apply the
light locally at the tumor 1 h p.i. of the nanobody–PS conjugates.
Clear differences were observed on the values of intrinsic ﬂuores-
cence of the two EGFR targeted nanobody–PS conjugates, where higher
values were obtained for 7D12-9G8–PS in the tumor at all times, com-
pared to 7D12–PS. Thus, 7D12-9G8–PS seems to be the best nanobody
format to carry PS to the tumor. Although additional experiments are
needed to further clarify these differences, at this pointwe can speculate
that these could be related to the different nanobody formats, i.e. mono-
valent versus biparatopic, and their different distribution and binding in
tumors. In fact, the enhanced internalization documented for 7D12-9G8
in vitro [25] could play an important role.We have observedmore inter-
nalization of 7D12-9G8–PS than 7D12–PS, after 30 min incubation
in vitro, thus at 1 h after i.v. injection it is well possible that the same
trend can affect the results observed in vivo. In addition, differences
are to some extent related to the different DOC of the nanobody–PS,
as this was 0.5 for 7D12–PS and 1.0 for 7D12-9G8–PS. Although, the
equal dose of protein given (in micrograms) allowed the injection of
equal amounts of PS molecules per mouse, approximately half of the
7D12 molecules were conjugated to PS, whereas all molecules of
7D12-9G8 injected contained a PS. As a consequence, competition of
conjugated 7D12–PS and unconjugated 7D12 for binding to the EGFR,
could have contributed to the lower intrinsic ﬂuorescence and TBRs of
7D12–PS, compared to 7D12-9G8–PS.
In order to further elucidate themechanism(s) underlying the efﬁcacy
of our conjugates compared to that of a mAb–PS conjugate, we also per-
formed quantitative spectroscopy in animals 24 h after the injection of
cetuximab–PS (which was the time point employed in previous studies
for mAb–PSs [15], with DOC of 3.0, equivalent PS injected as the other
mice). At this time point the average value of Qfμaf was 0.0374 ± 0.0045,
0.0057 ± 0.0019 and 0.0036 ± 0.0007, in tumor, normal tongue, and in
skin, respectively, with a corresponding TBR of 6.5 ± 0.9. These tumor
values for Qfμaf are signiﬁcantly greater (~7.5-fold) than the maximum
ﬂuorescence intensity early after the injection of 7D12-9G8–PS and
the TBR exceeds the TBR found for 7D12-9G8–PS at 1 h p.i. Despite the
same dose of PS had been injected with this mAb–PS as with the
nanobody–PS conjugates, these results suggest that the mAb–PS is the
most effective carrier for higher accumulation of PS at the tumor. This
is likely a consequence of a combination of the longer half-life of
cetuximab–PS in the blood stream, which leads to later accumulation of
the conjugate at the tumor (i.e. 24 h instead of 1 h p.i.), and the higher
DOCof cetuximab–PS. It is important to note that quantitative spectrosco-
py provides a volume average signal (over ~1 mm3) and does not retain
any information on themicroscopic distribution of the conjugates. There-
fore, additional studies are required to compare the microscopic localiza-
tion of the different conjugates.
To further validate the 1 h p.i. as being the optimal time point for
illumination, a number of mice (n= 2)were subjected to in vivo optical
Fig. 3. Quantitative ﬂuorescence spectroscopy for selecting the illumination time point. (A) Local assessment of the intrinsic ﬂuorescence of the nanobody–PS conjugates at the tumor,
normal tongue and skin, as an indication of their pharmacokinetics. Intrinsic ﬂuorescence, Qfμaf , is the product of the ﬂuorescence quantum yield of the PS and its absorption coefﬁcient
at 660 nm. Average values of Qfμaf are calculated from 0 to 24 h after injection of nanobody–PS conjugates. (B) Tumor-to-background ratio (TBR) at 1 h and 24 h p.i. of the different
nanobody–PS conjugates, calculated from intrinsic ﬂuorescence measurements. Error bars represent the standard deviation of the calculated TBRs.
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conjugates. Clearly, very little ﬂuorescence is observed at the tongue
when R2–PS was injected, in contrast to the highly ﬂuorescent tongues
shown when mice were injected with either 7D12–PS or 7D12-9G8–PS
(Fig. 4A). These images support the speciﬁcity documented earlier
(Fig. 3). In parallel, tongues of mice were collected 1 h p.i. of the
nanobody–PS conjugates and were processed for ﬂuorescence
imaging and histology. These analyses conﬁrmed that both EGFR targeted
conjugates are tumor speciﬁc. Already at 1 h p.i. of 7D12–PS and 7D12-
9G8–PS, a clear colocalization of ﬂuorescence and tumor could be
observed, conﬁrming tumor speciﬁcity (Fig. 4B). No tumor accumu-
lation was observed in sections of tongues of mice injected with the
control R2–PS. Importantly, nanobody–PS conjugates showed a homoge-
nous distribution through the solid tumor,which is in agreementwith our
previous optical imaging study [31] and is expected to contribute to treat-
ment efﬁcacy.
3.4. In vivo evaluation of nanobody-targeted PDT
Besides the best time point for illumination (i.e. 1 h p.i.), an impor-
tant consideration for optimizing the efﬁcacy of the nanobody–PS
conjugates in vivo is the choice of PDT illumination parameters: ﬂuence
and ﬂuence rate. The latter was chosen to be 50 mW/cm2 to avoid any
heating of the illuminated tissue and to maximize the ability of the
tumor vasculature to supply oxygen during illumination. The former
parameter, the therapeutic light ﬂuence (or dose) was chosen to be
100 J/cm2 in order to maximize PDT efﬁcacy, considering the penetra-
tion of the laser light (690 nm, which is the excitation maximum forthis PS) in the tongue and the inevitable photobleaching of the PS dur-
ing the illumination. It is important to note that this light ﬂuence may
be reduced, in the future, after a full optimization of the illumination pa-
rameters has been performed. Given the difﬁculty of light ﬂuence (rate)
treatment planning in mice, we chose to accept the potential over-
treatment of the underlying normal tissue in the present study.
Thus, 1 h p.i. of the nanobody–PS conjugates, illumination was per-
formed superﬁcially on the tongue of mice. As positive control for
in vivo PDT, we injectedmicewith cetuximab–PS, whichwere then illu-
minated 24 h p.i., similar to the study ofMitsunaga et al. [15]. Thereafter,
to determinewhether the conjugateswere capable of inducing selective
tumor cell death in vivo, micewere sacriﬁced at 24 h post-PDT and their
tongues were processed for histological analyses. All the controls, i.e.
light only and R2–PS, 7D12–PS and 7D12-9G8–PS without application
of light, presented a viable and dense tumor (H&E), aswell as numerous
blood vessels (CD31 staining), indicating that neither light alone, nor
the nanobody–PS conjugates without light were capable of inducing
damage (Fig. 5A). The antibody-targeted PDT led to tumor damage,
which validates the model and procedure here employed, although
with a broad variation of degree of necrosis, ranging from 25 to 70%
(median 57.5%, Fig. 5A, B). Numerous blood vessels remained intact
after this PDT, as observed in the correspondingCD31 staining. An unex-
pected mild to moderate tumor damage was obtained with R2–PS
(median 42.5%, range 20–50% necrosis, Fig. 5B), likely a bystander effect
due to vascular damage, as suggested by the heavily coagulated blood
vessels observed just below the tip of the tongue and the absence of
CD31 staining in the tumor area, though viable tumor is still observed
(Fig. 5A, Table 1). Whether R2–PS is speciﬁcally associating with
Fig. 4. EGFR-targeted nanobody–PS conjugates speciﬁcally localize in tumors. (A) Optical imaging of mice 1 h p.i. of the nanobody–PS conjugates. Images were obtained with a Pearl
imaging system. Brightness of individual illustrations is manually adjusted to highlight the location of the ﬂuorescence. Asterisks (*) indicate lymph nodes. (B) Fluorescence imaging of
the PS (in dark) and H&E staining of sections of tongues obtained from mice 1 h p.i. of the nanobody–PS conjugates. OSC tumors are distinguished at the higher half of the tongues, by
a characteristic dense mass of tumor cells, delimited by a dark line.
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explanation for these observations. On the contrary, for both nanobody
formats targeting EGFR, a more homogenous damage to the tumor
is observed, reaching even 90% of necrosis (Fig. 5A, B). In the case of
7D12–PS, a very localized and reproducible damage was induced at
the tumor site (median 80%, range 80–90% necrosis), with minimal
effect on the CD31 staining of blood vessels around the tumor (brown
color present), whereas inside the tumor no CD31 staining was
observed (Fig. 5A, Table 1). With 7D12-9G8–PS, some variation be-
tween mice was observed in the extent of damage induced (median
80%, range 60–90% necrosis), and slightlymore coagulationwas observed
at the blood vessels surrounding the tumor (compared to 7D12–PS)
(Fig. 5A, Table 1). Notably, the two EGFR targeted nanobody-
photosensitizer conjugates were the only format of conjugates capable
of inducing 90% necrosis (Fig. 5B). 7D12–PS induced signiﬁcantly more
necrosis compared to both R2–PS (p = 0.0256) and cetuximab–PS
(p = 0.0265) (Fig. 5B). Due to the variation in effect induced in mice
with 7D12-9G8–PS, the extent of necrosis was signiﬁcantly higher com-
pared to R2–PS (p = 0.0284), but not compared to cetuximab–PS (p =
0.1102) (Fig. 5B).
Interestingly, although spectroscopy experiments showed a sig-
niﬁcantly higher concentration of cetuximab–PS at the time point of
irradiation compared to 7D12-9G8–PS and 7D12–PS, signiﬁcantly
more necrosis was observed with the nanobody–PS conjugates. In fact,
these in vivo results suggest that the most effective and reproducible
treatment was obtained with the monovalent 7D12–PS conjugate. Im-
portantly, we realize that at this point conclusions should be verycarefully drawn as these are in fact three different antibody formats
and thus three independent carrier systems for PS, here investigated
side-by-side in very particular conditions. Nevertheless, these results
are remarkable, in light of the observations obtained with quantitative
ﬂuorescence spectroscopy revealing a lower concentration of PS and
lower TBR obtained with the 7D12–PS conjugate, compared to 7D12-
9G8–PS or cetuximab–PS. Furthermore, while 7D12-9G8–PS was more
toxic than 7D12–PS in vitro (Fig. 2), also in respect of induction of necro-
sis (Supplementary Material, Fig. S3), in vivo efﬁcacy studies point to a
higher phototoxicity induced by 7D12–PS. This increase in efﬁcacy of
themonovalent 7D12–PS could be due to its small size, which likely en-
ables better penetration into the interior of tumors and a more homog-
enous distribution. It is well accepted that the diffusion of molecules
from the blood vessels and their subsequent penetration through
tissues is inﬂuenced by factors such as molecular weight, size, charge,
afﬁnity, and antigen expression among others [59,60]. Furthermore,
using small nanobodies, the PS is in closer proximity to the cell mem-
brane which could increase phototoxicity. More studies are certainly
needed to better understand the differences observed in PDT efﬁcacy
between 7D12–PS and 7D12-9G8–PS in vivo, and future studies will
also demonstrate whether the signiﬁcant differences in necrosis will re-
sult in differences in survival. However, at this point, it is clearly sug-
gested that the overall amount of PS accumulated in the tumor is not
per se the limiting factor for efﬁcacy, but theway it is distributed is likely
very critical. Themore homogenous and reproducible degree of damage
induced by 7D12–PS, as compared to cetuximab–PS, is in agreement
with our former study showing differences in intratumoral distribution
Fig. 5. In vivo tumor speciﬁc phototoxicity of nanobody–PS conjugates. (A) Sections of tongues of mice collected 24 h post-PDT, processed for histology (H&E) and anti-CD31 staining to
assess phototoxicity of the different treatments: intravenous administration of R2–PS, 7D12–PS or 7D12-9G8–PS followed by illumination 1 h p.i., or cetuximab–PS followed by
illumination 24 h p.i. These are compared to the controls: light alone or each nanobody–PS conjugate without illumination. Each image is representative of the results obtained for that
group. Areas of viable or necrotic tumor are indicated and blood vessels are highlighted by the anti-CD31 staining (in brown). (B) Percentages (%) of tumor necrosis obtained for each
single treatment are depicted together with the median value. (C) Representative examples of damage to the epithelium, muscle cells, endothelium, and of edema and inﬁltration of
neutrophils indicating recruitment of immune cells.
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Watanabe et al. [24] have recently compared a mAb–PS (150 kDa)
with a minibody–PS (80 kDa) and a diabody–PS (50 kDa), where the
PS was IRDye700DX, and found that the use of the smallest fragment
(in this case a diabody) resulted in the shortest time interval between
injection and light exposure without compromising therapeutic efﬁca-
cy. These results differ from ours, in that we found a difference in pho-
totoxicity with our nanobody–PS conjugates (15 or 30 kDa), to the
advantage of the smaller nanobody–PS conjugates compared to theantibody–PS conjugate. The disparity between these results could be ex-
plained by the differences in format and/or size of diabody–PS and
nanobody–PS conjugates.
Besides the extent of damaged tumor, damage to the epithelium and
other features were also scored (Table 1, with examples given in
Fig. 5C). Overall, no signiﬁcant damage to the epithelium was induced
by any of the treatments, other than the damage likely associated with
handling of the tongues with a pincette. Damage to muscle cells was
common to all treatments on the cells nearest to the tumor, but absent
Table 1
Several features are scored to characterize the damage observed in Fig. 5.
Controls R2–PS Cet–PS 7D12–PS 7D12-9G8–PS
Edema + ++ ++ ++ ++/+++
Presence of mast cells + +/++ + + +
Presence of neutrophils − +/++ +++ ++ +/++
Damage to muscle cells
Around the tumor − + + +/++ +
Away from tumor − − − − −
Damage to epithelium − 5–10% 5–10% 5–10% 5%
Damage to blood vessels (H&E)
Around the tumor − ++ + +/++ ++
Away from tumor − − − − −
Absence of CD31 stain
Inside the tumor − ++/+++ ++/+++ +++ ++/+++
Around the tumor − + + + +
Away from the tumor − − − − −
Remarks − Coagulation − − −
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different groups, although the trend was a more pronounced damaged
in the tumor or in blood vessels surrounding the tumor and no damage
further away from the tumor. Due to necrosis, the damage to muscle
cells and blood vessels inside the tumor was not possible to score accu-
rately from H&E sections. Edema was always present, while the extent
of inﬁltration of neutrophils or mast cells varied, suggesting that PDT
mediated by this PS (IRDye700DX) is also capable of recruiting immune
cells. Future studies will have to prove how these inﬂammatory re-
sponses affect overall treatment efﬁcacy.
Vascular targeted PDT is very dependent on the time interval be-
tween PS administration and illumination. Here, we have selected 1 h
p.i. for the nanobody–PS conjugates and 24 h p.i. for cetuximab–PS, to
promote tumor targeted PDT. Shorter intervals could possibly lead to
more vascular damage, also risking damage to normal tissues. Clearly,
the time point selected was appropriate for 7D12–PS and 7D12-9G8–
PS as this resulted inminimal damage of blood vessels and normalmus-
cle cells around the tumor and no damage of blood vessel and normal
muscle cells away from the tumor area. These details also indicate that
high TBRs are not a requirement, in this particular form of PDT, to dam-
age the tumor and spare normal tissue (TBRs obtained were 1.8 ± 0.3
for 7D12–PS and 3.8 ± 0.5 for 7D12-9G8–PS). This is an interesting ob-
servation that could have important implications for the PDT ﬁeld. Pos-
sibly, it is an effect of this particular PS, as this PS does not lead to any
damage unless it is conjugated to a targeting molecule (nanobody)
that binds to cells. Furthermore, the observation of minimal damage
around the tumor also suggests appropriate selection of the ﬂuence
for the illumination. In fact, as much as the laser was pointed to the
tumor, normal tissue surrounding it was certainly also exposed to the il-
lumination to some extent. Additionally, the light only control (Fig. 5A)
also proved that the selected parameters are safe for normal tissues.
Further in vivo research focused on varying nanobody–PS conjugate
dose, illumination time point, and ﬂuences for shorter treatment
times, could optimize this protocol further. In such protocol optimiza-
tion, quantitative ﬂuorescence spectroscopy may be of substantial ben-
eﬁt, allowing patient- and tumor-speciﬁc planning for illuminations.
The considerable efforts made in the ﬁeld to render PDT tumor spe-
ciﬁc [14,61–63] have recently resulted in ﬁrst-in-human trials, such as
NCT02422979 (clinicaltrials.gov), which is testing an antibody–PS con-
jugate composed of cetuximab and IRDye700DX. This trial will certainly
have an impact in the ﬁeld and hopefully stimulate additional trials that
will encourage the use of targeted PDT as a standard treatment in the
clinic. Even though antibody-targeted PDT has now entered a clinical
trial, as demonstrated in this study, nanobody-targeted PDT has the po-
tential to even further improve clinical PDT: through rapid accumula-
tion and fast clearance of the conjugates, enabling light application
very shortly after conjugate administration and minimizing possible
photosensitivity. Thesewould likely bring beneﬁts in respect of hospital
management and costs involved per treatment. In fact, nanobody-targeted PDT has great potential to be translated to the clinic. First, be-
cause the PS investigated here is already being employed in a clinical
trial, and second, because nanobodies have been in clinical trials for sev-
eral years in areas other than oncology (e.g. antithrombotic nanobody
[64]). The possibility for clinical translation surely should encourage ad-
ditional research to further explore this approach of nanobody-targeted
PDT.
4. Conclusions
Overall, the EGFR targeted nanobody–PS conjugates 7D12–PS and
7D12-9G8–PS are selective and potent PDT agents that speciﬁcally accu-
mulate in tumors in vivo. Upon local illumination within 1 h after
administration, these conjugates lead to pronounced tumor necrosis
and to the inﬁltration of immune cells. This study highlights the thera-
peutic potential of these novel nanomedicines and stimulates further
research, contributing to the exploration of nanobody-targeted PDT.
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